Story · Medicine & Biotech
New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical Trial
2 outlets · first reported by CU Anschutz News on · latest · 6 hours of coverage
In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with… (CU Anschutz News)
Coverage, in order
-
New Treatment Strategy for Down Syndrome Shows Promise in Phase 2 Clinical TrialIn a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with…
-
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trialIn a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.